ATE382148T1 - Antikörper für apoptosemarker und anwendungsverfahren - Google Patents

Antikörper für apoptosemarker und anwendungsverfahren

Info

Publication number
ATE382148T1
ATE382148T1 AT99948459T AT99948459T ATE382148T1 AT E382148 T1 ATE382148 T1 AT E382148T1 AT 99948459 T AT99948459 T AT 99948459T AT 99948459 T AT99948459 T AT 99948459T AT E382148 T1 ATE382148 T1 AT E382148T1
Authority
AT
Austria
Prior art keywords
antibodies
methods
apoptosis
application
apoptosis markers
Prior art date
Application number
AT99948459T
Other languages
English (en)
Inventor
Terry Riss
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Application granted granted Critical
Publication of ATE382148T1 publication Critical patent/ATE382148T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99948459T 1998-09-24 1999-09-24 Antikörper für apoptosemarker und anwendungsverfahren ATE382148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10192098P 1998-09-24 1998-09-24

Publications (1)

Publication Number Publication Date
ATE382148T1 true ATE382148T1 (de) 2008-01-15

Family

ID=22287166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948459T ATE382148T1 (de) 1998-09-24 1999-09-24 Antikörper für apoptosemarker und anwendungsverfahren

Country Status (6)

Country Link
US (3) US6350452B1 (de)
EP (1) EP1116029B1 (de)
AT (1) ATE382148T1 (de)
AU (1) AU6162999A (de)
DE (1) DE69937835T2 (de)
WO (1) WO2000017648A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US6350452B1 (en) * 1998-09-24 2002-02-26 Promega Corporation Apoptosis marker antibodies and methods of use
ATE271691T1 (de) * 2000-01-12 2004-08-15 Ventana Med Syst Inc Verfahren zum nachweis der effektivität einer krebstherapie
EP1301786B1 (de) * 2000-07-21 2005-11-30 Evotec AG Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US6982152B2 (en) * 2002-04-17 2006-01-03 Promega Corporation Cytotoxicity assay
DE60331310D1 (de) * 2002-06-26 2010-04-01 Univ Louisville Res Found Verfahren zum apoptosenachweis
FR2863053B1 (fr) * 2003-11-28 2007-04-06 Univ Claude Bernard Lyon Nouvelles sondes hybrides a luminescence exaltee
CN1316037C (zh) * 2003-12-19 2007-05-16 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
CN102747140A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070190580A1 (en) * 2005-10-31 2007-08-16 Beckman Coulter, Inc. Immunoassay of Fragments of Insulin-Like Growth Factor Binding Proteins
KR101433971B1 (ko) * 2006-06-20 2014-08-25 제넨테크, 인크. 클라트린-경로 성분의 단편을 검출함으로써 세포자멸을 관찰하기 위한 방법 및 물질
US20090221004A1 (en) * 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
US20090226914A1 (en) * 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
WO2010021822A2 (en) 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US9249231B2 (en) 2010-11-05 2016-02-02 Cell Signaling Technology, Inc. Motif-specific and context-independent antibodies that specifically bind to a cleaved caspase motif
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
US9594081B2 (en) 2011-06-20 2017-03-14 Proterixbio, Inc. Methods and systems for the rapid characterization of functional biological molecules
HK1251488A1 (zh) 2015-05-05 2019-02-01 The University Of Louisville Research Foundation, Inc. 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
CN110563840B (zh) * 2019-04-07 2021-06-01 北京利德曼生化股份有限公司 抗甘胆酸单克隆抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4927916A (en) 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
AU635008B2 (en) 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US5736348A (en) 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
US5387504A (en) * 1992-09-30 1995-02-07 Merck & Co., Inc. Monospecific antibodies and assay system for detecting stromelysin cleavage products
WO1995015084A1 (en) * 1993-11-30 1995-06-08 Lxr Biotechnology Inc. Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
US5536639A (en) 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US5594116A (en) 1995-11-08 1997-01-14 Promega Corporation Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
WO1998052297A2 (en) 1997-05-15 1998-11-19 Spectraplex, Inc. Parallel transmission method with diverse physical channel allocation
JP2002511748A (ja) * 1997-05-19 2002-04-16 カイロン コーポレイション アポトーシス誘導性ゲルゾリン配列
WO1999016789A1 (en) * 1997-09-30 1999-04-08 Peviva Ab Apoptosis-related compounds and their use
US6350452B1 (en) * 1998-09-24 2002-02-26 Promega Corporation Apoptosis marker antibodies and methods of use
FR2785053A1 (fr) 1998-10-21 2000-04-28 Centre Nat Rech Scient Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) et de detection de l'activite inhibitrice ou activatrice d'un inhibiteur ou d'un activateur de cette enzyme
CA2363984A1 (en) * 1999-04-15 2000-10-26 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use

Also Published As

Publication number Publication date
AU6162999A (en) 2000-04-10
EP1116029A4 (de) 2004-12-15
DE69937835D1 (de) 2008-02-07
EP1116029B1 (de) 2007-12-26
DE69937835T2 (de) 2009-01-02
US20060166294A1 (en) 2006-07-27
WO2000017648A1 (en) 2000-03-30
EP1116029A1 (de) 2001-07-18
US20020102268A1 (en) 2002-08-01
US7037664B2 (en) 2006-05-02
US6350452B1 (en) 2002-02-26

Similar Documents

Publication Publication Date Title
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
DK0921395T3 (da) Assays til måling af proteinfragmenter i biologiske medier
DE602004019812D1 (de) Marker für neuromyelitis optica
ATE458831T1 (de) Verfahren zum nachweis von lungenneoplasmen in fäkalen proben
IS5547A (is) Forlyf fyrir tálma við aspartílprótínkljúfum
BR9508151A (pt) Oligopeptídeo testes para determinar a atividade proteolítica de antígeno livre específico para próstata em uma amostra e para identificar compostos que inibem atividade proteolítica de antígeno específico para próstata e conjugado
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
DK1137943T3 (da) Fremgangsmåde til påvisning af cancer og reagenser
ATE393240T1 (de) Verfahren zum nachweis von prostatakrebs
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
DE602004026888D1 (de) Kinase- und phosphatasetests
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
BR9812783A (pt) "sistemas de detecção para o registro de interações e as relações funcionais de proteìnas"
DK1336109T3 (da) Kit og fremgangsmåde til at påvise proteinet EMS-1
ATE389881T1 (de) Detektion von kleinen molekülen mit piezo- elektrischem sensor
DE60234465D1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
DE60229043D1 (de) Rearrangierte plattenepithelkarzinomantigen-gene ii
ATE247831T1 (de) Verfahren zum nachweis von autoimmun-pathologien
DE60331414D1 (de) Aggrecanase-1- und -2-peptidsubstrate und verfahren
IL151564A0 (en) Potassium channel proteins
DE60040010D1 (de) Ein Verfahren zum Auffinden vom Prostatakrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1116029

Country of ref document: EP

REN Ceased due to non-payment of the annual fee